• AC Immune flagged new early human imaging data for its first-in-class TDP-43 PET tracer from studies in FTD and ALS.
• Additional AAIC 2026 presentations include Phase 1 progress for an oral, brain-penetrant NLRP3 inhibitor, due July 12-15 in London.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700OMX_____CNEWS_EN_GNW1001211573_en) on July 07, 2026, and is solely responsible for the information contained therein.